Amedisys Stock Intrinsic Value – AMEDISYS Reports Second Quarter Earnings for Fiscal Year 2023 on June 30th
July 28, 2023
🌥️Earnings Overview
AMEDISYS ($NASDAQ:AMED) reported total revenue of USD 553.0 million for the second quarter of fiscal year 2023, ending June 30th 2023. This was a 0.9% decrease in comparison to the same period the previous year. Net income, meanwhile, was reported to be USD -80.3 million, a decrease from the 29.6 million reported in the prior year.
Price History
On the same day, the company’s stock opened at $91.0 and closed the day at $89.8, representing a 1.3% decrease from its last closing price of $91.0. Looking ahead, AMEDISYS is determined to continue providing quality services to its clients and grow its business. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Amedisys. More…
| Total Revenues | Net Income | Net Margin |
| 2.23k | 2.33 | 3.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Amedisys. More…
| Operations | Investing | Financing |
| 113.97 | 35.25 | -86.83 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Amedisys. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.98k | 921.64 | 30.87 |
Key Ratios Snapshot
Some of the financial key ratios for Amedisys are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.2% | -2.9% | 3.3% |
| FCF Margin | ROE | ROA |
| 4.5% | 4.5% | 2.3% |
Analysis – Amedisys Stock Intrinsic Value
At GoodWhale, we conducted an analysis of AMEDISYS‘s fundamentals to determine the fair value of its stock. Our proprietary Valuation Line came up with a figure of $172.6 for the fair value of an AMEDISYS share. Currently, the stock is trading at $89.8, which is significantly lower than the fair value, translating to a 48.0% discount. This indicates that AMEDISYS’s stock is currently undervalued and now may be an attractive entry point for investors. More…
Peers
Its competitors include National Healthcare Corp, Aveanna Healthcare Holdings Inc, and Nova Leap Health Corp.
– National Healthcare Corp ($NYSEAM:NHC)
National Healthcare Corporation is a diversified healthcare services company that owns and operates long-term care facilities, hospitals, home health agencies, and hospice care businesses. The company has a market capitalization of $942.75 million and a return on equity of 2.65%. National Healthcare Corporation is headquartered in Nashville, Tennessee.
– Aveanna Healthcare Holdings Inc ($NASDAQ:AVAH)
Aveanna Healthcare Holdings Inc is a publicly traded company that provides health care services. The company has a market capitalization of 290.03 million as of 2022 and a return on equity of -71.08%. The company’s primary business is providing in-home health care services to patients. The company operates in the United States, Canada, and Puerto Rico.
– Nova Leap Health Corp ($TSXV:NLH)
Nova Leap Health Corp is a Canadian publicly traded company with a market cap of 23.25M as of 2022. The company is a provider of home health care services. The company has a Return on Equity of 1.6%. The company’s services include personal care, nursing, and homemaking services.
Summary
Investors looking at AMEDISYS may be disappointed with their second quarter fiscal year 2023 results. Revenue fell by 0.9% year-on-year to USD 553.0 million, and net income was USD -80.3 million, a decrease of USD 29.6 million from the prior year.
However, their success in other areas is worth considering. They recently made a partnership to increase their home health business, and have continued to make progress on their technology initiatives. Investors should consider the company’s further potential and continue to monitor for any updates to their strategies and progress.
